UA117121C2 - Біспецифічне антитіло до egfr/с-мет - Google Patents

Біспецифічне антитіло до egfr/с-мет

Info

Publication number
UA117121C2
UA117121C2 UAA201506064A UAA201506064A UA117121C2 UA 117121 C2 UA117121 C2 UA 117121C2 UA A201506064 A UAA201506064 A UA A201506064A UA A201506064 A UAA201506064 A UA A201506064A UA 117121 C2 UA117121 C2 UA 117121C2
Authority
UA
Ukraine
Prior art keywords
met
egfr
bispecific antibody
specific antibody
expressing egfr
Prior art date
Application number
UAA201506064A
Other languages
English (en)
Ukrainian (uk)
Inventor
Марк Чіу
Шері Мурс
Йост Нейссен
Пауль Паррен
Яніне Схюрман
Original Assignee
Янссен Байотек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50728148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA117121(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Байотек, Інк. filed Critical Янссен Байотек, Інк.
Publication of UA117121C2 publication Critical patent/UA117121C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201506064A 2012-11-21 2013-11-21 Біспецифічне антитіло до egfr/с-мет UA117121C2 (uk)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728912P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
US201361864717P 2013-08-12 2013-08-12
US201361892797P 2013-10-18 2013-10-18
PCT/US2013/071288 WO2014081954A1 (en) 2012-11-21 2013-11-21 BISPECIFIC EGFR/c-Met ANTIBODIES

Publications (1)

Publication Number Publication Date
UA117121C2 true UA117121C2 (uk) 2018-06-25

Family

ID=50728148

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201506064A UA117121C2 (uk) 2012-11-21 2013-11-21 Біспецифічне антитіло до egfr/с-мет

Country Status (36)

Country Link
US (3) US9593164B2 (enExample)
EP (4) EP4420727A3 (enExample)
JP (6) JP6423357B2 (enExample)
KR (5) KR102373193B1 (enExample)
CN (2) CN113201073A (enExample)
AU (4) AU2013347962B2 (enExample)
BR (1) BR112015011717B1 (enExample)
CA (2) CA3182876A1 (enExample)
CL (1) CL2015001356A1 (enExample)
CY (2) CY1121270T1 (enExample)
DK (2) DK2922872T3 (enExample)
EA (1) EA031184B1 (enExample)
ES (3) ES2700231T3 (enExample)
FI (1) FIC20220016I1 (enExample)
FR (1) FR22C1018I2 (enExample)
HR (2) HRP20182128T1 (enExample)
HU (3) HUE041499T2 (enExample)
IL (1) IL238796B (enExample)
LT (3) LT2922872T (enExample)
LU (1) LUC00257I2 (enExample)
MX (1) MX361088B (enExample)
MY (1) MY172867A (enExample)
NI (1) NI201500069A (enExample)
NL (1) NL301173I2 (enExample)
NO (1) NO2022012I1 (enExample)
NZ (1) NZ708352A (enExample)
PE (1) PE20151181A1 (enExample)
PH (1) PH12015501118A1 (enExample)
PL (1) PL2922872T3 (enExample)
PT (2) PT3447069T (enExample)
RS (2) RS61057B1 (enExample)
SG (1) SG11201503938VA (enExample)
SI (2) SI2922872T1 (enExample)
SM (2) SMT202000619T1 (enExample)
UA (1) UA117121C2 (enExample)
WO (1) WO2014081954A1 (enExample)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
CN102711810B (zh) * 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
EP3904391B1 (en) * 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
IN2014CN03887A (enExample) 2011-10-27 2015-10-16 Genmab As
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체
US10196446B2 (en) 2013-10-14 2019-02-05 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
HUE049437T2 (hu) * 2014-02-04 2020-09-28 Astellas Pharma Inc Hatóanyagként heterociklusos diamino-karboxamid vegyületet tartalmazó gyógyászati készítmény
CA2941030C (en) 2014-02-28 2025-05-13 Merus N.V. ANTIBODIES THAT BIND TO EGFR AND ERBB3
KR102309881B1 (ko) 2014-11-21 2021-10-06 삼성전자주식회사 c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물
CN107427515B (zh) * 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
WO2016100232A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
US10717783B2 (en) * 2014-12-22 2020-07-21 Zeren Gao Bispecific tetravalent antibodies and methods of making and using thereof
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
WO2016182513A1 (en) * 2015-05-13 2016-11-17 Singapore Health Services Pte Ltd Profiling of hepatocellular carcinoma and applications thereof
JP7296728B2 (ja) * 2015-10-23 2023-06-23 メルス ナムローゼ フェンノートシャップ 癌の成長を抑制する結合分子
EP3368571B1 (en) 2015-10-30 2022-12-07 The Regents of The University of California Transforming growth factor-beta-responsive polypeptides and their methods for use
JP2019500011A (ja) 2015-11-03 2019-01-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
JP7014724B2 (ja) * 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Ｆａｂ免疫グロブリンおよびその使用
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
KR101985299B1 (ko) * 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
WO2017223180A2 (en) * 2016-06-21 2017-12-28 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CA3039136A1 (en) 2016-09-02 2018-03-08 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3541423A4 (en) 2016-11-18 2020-10-07 The Regents of The University of California MODIFIED ANTIBODIES AND THEIR USES
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
JP7737220B2 (ja) 2017-03-31 2025-09-10 メルス ナムローゼ フェンノートシャップ ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
EP3625264B9 (en) 2017-05-17 2023-10-25 Merus N.V. Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
EP3630844A4 (en) * 2017-05-30 2021-03-03 Chong Kun Dang Pharmaceutical Corp. NOVEL ANTI-C-MET ANTIBODY AND USE OF IT
WO2018221969A1 (en) * 2017-05-30 2018-12-06 Chong Kun Dang Pharmaceutical Corp. A novel anti-c-met antibody and use thereof
RS66708B9 (sr) * 2017-08-09 2025-08-29 Merus Nv Antitela koja se vezuju za egfr i cmet
CA3074317C (en) * 2017-08-25 2024-06-18 Janssen Biotech, Inc. Fc.gamma.rii binding fibronectin type iii domains, their conjugates and multispecific molecules comprising them
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
MX2020012598A (es) 2018-05-24 2021-05-27 Janssen Biotech Inc Agentes aglutinantes del psma y usos de estos.
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
AU2019338207B2 (en) * 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
MY205905A (en) 2018-10-22 2024-11-20 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
MX2021010265A (es) * 2019-02-26 2021-09-23 Janssen Biotech Inc Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos.
AR118720A1 (es) 2019-04-19 2021-10-27 Janssen Biotech Inc Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3
BR112021022828A2 (pt) * 2019-05-14 2022-04-12 Janssen Biotech Inc Terapias combinadas com anticorpos biespecíficos anti-egfr/c-met e inibidores de egfr tirosina-quinase de terceira geração
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
MY208668A (en) 2019-05-14 2025-05-23 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and 3rd generation egfr tyrosine kinase inhibitors
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
BR112022015140A2 (pt) * 2020-02-12 2022-10-11 Janssen Biotech Inc Tratamento de pacientes que têm mutações de salto do éxon 14 de c-met
TWI923583B (zh) 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
EP4204455A4 (en) * 2020-08-25 2024-10-16 Janssen Biotech, Inc. Treatment of non-small cell lung cancer with egfr mutations
AR123340A1 (es) * 2020-08-26 2022-11-23 Janssen Biotech Inc FORMULACIONES ESTABLES QUE COMPRENDEN UN ANTICUERPO BIESPECÍFICO PARA EGFR / c-MET
US20230321087A1 (en) * 2020-09-14 2023-10-12 Janssen Pharmaceutica Nv Fgfr inhibitor combination therapies
WO2022104236A2 (en) * 2020-11-16 2022-05-19 Ab Therapeutics, Inc. Multispecific antibodies and uses thereof
MX2023008909A (es) 2021-01-28 2023-10-23 Janssen Biotech Inc Proteínas de unión a psma y usos de estas.
IL305700A (en) * 2021-03-09 2023-11-01 Janssen Biotech Inc Treatment of cancers lacking EFGR-activating mutations
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
CN117177740A (zh) * 2021-04-21 2023-12-05 詹森生物科技公司 高浓度双特异性抗体制剂
TW202309094A (zh) 2021-05-18 2023-03-01 美商健生生物科技公司 用於識別癌症患者以進行組合治療之方法
EP4372001A4 (en) * 2021-07-14 2025-02-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. ANTIGEN-BINDING MOLECULE SPECIFICALLY BINDING TO HGFR AND EGFR, AND PHARMACEUTICAL USE THEREOF
CN118339188A (zh) 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
CN118355030A (zh) * 2021-10-18 2024-07-16 拓维创新生物科技(香港)有限公司 抗EGFR抗体、抗cMET抗体、抗VEGF抗体、多特异性抗体及其用途
US20230183360A1 (en) * 2021-12-09 2023-06-15 Janssen Biotech, Inc. Use of Amivantamab to Treat Colorectal Cancer
EP4470565A1 (en) 2022-01-28 2024-12-04 OnQuality Pharmaceuticals China Ltd. Method for preventing or treating disease or disorder associated with antineoplastic agent
TW202342057A (zh) 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
WO2023155905A1 (zh) 2022-02-21 2023-08-24 上海岸阔医药科技有限公司 化合物及其用途
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法
CA3256857A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. EGFR/MET ANTIBODIES AND THEIR USES
CN119790073A (zh) 2022-06-30 2025-04-08 詹森生物科技公司 使用抗EGFR/抗Met抗体治疗胃癌或食道癌
WO2024109914A1 (zh) * 2022-11-24 2024-05-30 江苏恒瑞医药股份有限公司 一种包含特异性结合hgfr和egfr的双特异性抗体的药物组合物
AU2024236678A1 (en) 2023-03-13 2025-10-30 Janssen Biotech, Inc. Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
EP4680648A1 (en) * 2023-03-17 2026-01-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-her3 and anti-met antibodies and uses thereof
EP4454706A1 (en) * 2023-04-24 2024-10-30 Universität Stuttgart Novel egfr binding proteins
AU2024277829A1 (en) 2023-05-19 2025-12-04 Les Laboratoires Servier Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof
CA3228195A1 (en) 2023-05-23 2025-06-30 Janssen Biotech, Inc. Methods for treatment of non-small cell lung cancer (nsclc)
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
KR20260051102A (ko) * 2023-07-07 2026-04-15 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 Egfr/c-met 이중특이적 결합 단백질 및 이의 용도
EP4743494A1 (en) 2023-07-14 2026-05-20 Janssen Biotech, Inc. DOSING REGIMEN FOR THERAPIES INCLUDING BISPECIFIC ANTI-EGFR/C-MET ANTIBODIES
CN121969654A (zh) * 2023-08-02 2026-05-01 百泰生物药业有限公司 EGFR/c-Met双特异性抗体及其应用
IL326946A (en) 2023-09-05 2026-05-01 Janssen Biotech Inc Methods of treating non-small cell lung cancer
WO2025067492A1 (zh) * 2023-09-28 2025-04-03 上海翰森生物医药科技有限公司 一种双特异性抗体在制备治疗癌症的药物中的用途
WO2025079020A1 (en) 2023-10-12 2025-04-17 Janssen Biotech, Inc. First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
CN122161833A (zh) * 2023-11-15 2026-06-05 四川科伦博泰生物医药股份有限公司 靶向EGFR/c-MET的抗体-药物缀合物及其制备方法和用途
IL328594A (en) 2023-11-23 2026-07-01 Velavigo Bio Inc Binding molecule and antibody-drug conjugate and their uses
TW202532100A (zh) * 2023-12-22 2025-08-16 大陸商信達生物製藥（蘇州）有限公司 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用
TW202547867A (zh) 2024-01-16 2025-12-16 美商健生生物科技公司 使用阿米維單抗治療結腸直腸癌
WO2025158277A1 (en) 2024-01-22 2025-07-31 Janssen Biotech, Inc. Use of amivantamab to treat head and neck cancer
WO2025191459A1 (en) 2024-03-11 2025-09-18 Janssen Biotech, Inc. Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
CN121045388A (zh) * 2024-05-30 2025-12-02 英百瑞(杭州)生物医药有限公司 针对人c-Met和人EGFR的双特异性抗体及其用途
WO2025247330A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗EGFR×cMet双特异性抗体的药物偶联物及其用途
WO2026017120A1 (zh) * 2024-07-18 2026-01-22 信达生物制药(苏州)有限公司 抗cdh17/egfr/cd16a三特异性抗体及其用途
WO2026038160A1 (en) 2024-08-13 2026-02-19 Janssen Biotech, Inc. Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CA3278557A1 (en) 2024-08-13 2026-03-01 Janssen Biotech, Inc. Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
WO2026042017A1 (en) 2024-08-19 2026-02-26 Janssen Biotech, Inc. Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
WO2026086740A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use and method of bispecific antibody-drug conjugates for treating tumor diseases
WO2026086737A1 (en) 2024-10-21 2026-04-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Uses and methods of bispecific antibody-drug conjugates for treating tumor diseases
WO2026145588A1 (en) 2024-12-31 2026-07-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Use of egfr/c-met bispecific binding protein
WO2026152008A1 (en) 2025-01-10 2026-07-16 Oric Pharmaceuticals, Inc. Enozertinib for treating epidermal growth factor receptor (egfr) exon 20 mutant nsclc in combination with amivantamab

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69025946T2 (de) 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
AU658396B2 (en) 1991-03-06 1995-04-13 Merck Patent Gesellschaft Mit Beschrankter Haftung Humanized and chimeric monoclonal antibodies
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
DK1392359T4 (da) 2001-05-11 2013-06-10 Ludwig Inst For Cancer Res Ltd Specifikke bindingsproteiner og deres anvendelser.
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR100945108B1 (ko) * 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (ja) 2001-09-26 2010-12-22 アイシン精機株式会社 自動車用ドア
AU2003260786B2 (en) 2002-09-06 2008-03-13 Isogenica Limited In vitro peptide expression libraray
MXPA05008521A (es) 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
EA015363B1 (ru) * 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2005250484B2 (en) 2004-06-04 2011-08-11 Genentech, Inc. EGFR mutations
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
AU2008343595A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. A human non-antibody peptide or protein phage library
SG188802A1 (en) 2008-03-06 2013-04-30 Genentech Inc Combination therapy with c-met and egfr antagonists
PE20091827A1 (es) 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
KR20110044905A (ko) * 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
AU2009300328A1 (en) 2008-10-01 2010-04-08 Ludwig Institute For Cancer Research Methods for the treatment of cancer
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
CN102361884A (zh) * 2009-04-07 2012-02-22 罗氏格黎卡特股份公司 双特异性抗-ErbB-2/抗-c-Met抗体
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX2012002651A (es) * 2009-09-01 2012-05-22 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
CN102711810B (zh) 2009-11-30 2015-04-22 詹森生物科技公司 效应子功能已消除的抗体Fc区突变体
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
HUE029622T2 (en) 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin domain compositions, methods and uses
US9127319B2 (en) * 2010-06-15 2015-09-08 Alberto Bardelli MLK4 gene, a new diagnostic and prognostic marker in cancers
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
KR102276792B1 (ko) * 2011-10-10 2021-07-15 시티 오브 호프 메디토프와 메디토프-결합 항체 및 이들의 용도
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR102373193B1 (ko) * 2012-11-21 2022-03-10 얀센 바이오테크 인코포레이티드 이중특이성 EGFR/c-Met 항체

Also Published As

Publication number Publication date
ES2831374T3 (es) 2021-06-08
FR22C1018I2 (fr) 2023-05-05
AU2019200441B2 (en) 2021-01-28
CY1123550T1 (el) 2022-03-24
EA201590985A1 (ru) 2015-11-30
KR102961038B1 (ko) 2026-05-04
EP3808767A1 (en) 2021-04-21
SMT202000619T1 (it) 2021-01-05
US20140255408A1 (en) 2014-09-11
PL2922872T3 (pl) 2019-03-29
PH12015501118B1 (en) 2016-02-01
JP6773746B2 (ja) 2020-10-21
JP6423357B2 (ja) 2018-11-14
KR20260079389A (ko) 2026-06-01
EP2922872A1 (en) 2015-09-30
AU2013347962B2 (en) 2018-10-25
CL2015001356A1 (es) 2015-11-06
SMT201800624T1 (it) 2019-01-11
LT3447069T (lt) 2020-12-10
RS58192B1 (sr) 2019-03-29
NI201500069A (es) 2015-10-19
PT3447069T (pt) 2020-11-13
ES2700231T3 (es) 2019-02-14
MY172867A (en) 2019-12-13
IL238796B (en) 2019-06-30
JP2024026236A (ja) 2024-02-28
EP3808767B1 (en) 2023-12-06
DK2922872T3 (da) 2019-01-02
EP4420727A2 (en) 2024-08-28
EP3447069B1 (en) 2020-09-23
US9580508B2 (en) 2017-02-28
AU2021202394B2 (en) 2024-03-07
ES2971536T3 (es) 2024-06-05
EP4420727A3 (en) 2024-10-23
LT2922872T (lt) 2018-12-27
PT2922872T (pt) 2019-01-18
EP2922872A4 (en) 2016-07-06
SI2922872T1 (sl) 2019-01-31
US20140141000A1 (en) 2014-05-22
JP2026015326A (ja) 2026-01-29
HUE041499T2 (hu) 2019-05-28
NL301173I1 (nl) 2022-05-04
KR102795571B1 (ko) 2025-04-11
NO2022012I1 (no) 2022-05-06
JP7019771B2 (ja) 2022-02-15
CN104955838A (zh) 2015-09-30
MX361088B (es) 2018-11-26
BR112015011717A2 (pt) 2017-08-15
NL301173I2 (nl) 2022-06-15
CA3182876A1 (en) 2014-05-30
NZ708352A (en) 2019-10-25
AU2019200441A1 (en) 2019-02-07
HUE052548T2 (hu) 2021-05-28
WO2014081954A1 (en) 2014-05-30
CA2893505C (en) 2023-02-21
EA031184B1 (ru) 2018-11-30
KR20250054125A (ko) 2025-04-22
JP7756699B2 (ja) 2025-10-20
CY1121270T1 (el) 2020-05-29
DK3447069T3 (da) 2020-11-16
FR22C1018I1 (fr) 2022-06-17
KR20240005211A (ko) 2024-01-11
KR20220032654A (ko) 2022-03-15
JP2019048817A (ja) 2019-03-28
JP2021006561A (ja) 2021-01-21
FIC20220016I1 (fi) 2022-05-31
SG11201503938VA (en) 2015-06-29
US20170101475A1 (en) 2017-04-13
LUC00257I2 (enExample) 2025-04-25
HUS2200016I1 (hu) 2022-05-28
SI3447069T1 (sl) 2021-02-26
JP7397105B2 (ja) 2023-12-12
IL238796A0 (en) 2015-06-30
KR20150087365A (ko) 2015-07-29
MX2015006387A (es) 2015-12-03
AU2013347962A1 (en) 2015-05-28
EP3447069A1 (en) 2019-02-27
HRP20201848T1 (hr) 2021-01-08
LTC2922872I2 (enExample) 2024-09-10
BR112015011717B1 (pt) 2023-12-12
EP3808767C0 (en) 2023-12-06
AU2024203417A1 (en) 2024-06-13
PH12015501118A1 (en) 2016-02-01
PE20151181A1 (es) 2015-08-19
CN104955838B (zh) 2021-02-02
AU2021202394A1 (en) 2021-05-20
JP2016505537A (ja) 2016-02-25
LTPA2022507I1 (enExample) 2022-06-27
KR102373193B1 (ko) 2022-03-10
HRP20182128T1 (hr) 2019-02-08
US9695242B2 (en) 2017-07-04
EP2922872B1 (en) 2018-10-10
CN113201073A (zh) 2021-08-03
RS61057B1 (sr) 2020-12-31
JP2022062155A (ja) 2022-04-19
US9593164B2 (en) 2017-03-14
CA2893505A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
JO3714B1 (ar) تركيبات الجسم المضاد لـ cd70 و cd3
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
JO3792B1 (ar) تركيبات الجسم المضاد لـ flt3 و cd3
MY172867A (en) Bispecific egfr/c-met antibodies
MX2020009692A (es) Moleculas biespecificas de union a antigeno activadoras de celulas t.
MA40074A (fr) Composés liant ras multivalents
PH12015502293A1 (en) Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
EA202090956A2 (ru) Антитела к cd73 и их применения
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
MX375439B (es) Moleculas de union cd37 y sus inmunoconjugados.
EA201492101A1 (ru) Антитела против fcrn
MX2015010350A (es) Moleculas de union a antigeno biespecificas que activan la celula t.
NZ748133A (en) Agents for treatment of claudin expressing cancer diseases
EA201400178A1 (ru) Лечение рака молочной железы
EA201200999A1 (ru) Способы лечения рака молочной железы
MX2016014862A (es) Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2.
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
NZ715177A (en) Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
MX352373B (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
AR097996A1 (es) Anticuerpos
PE20151004A1 (es) Moleculas de union al dominio de fibronectina de tipo iii de egfr y c-met